The Effect of n-3 Fatty Acid Supplementation on Serum Levels, & Gene

Status Enrolling by invitation

Clinical Trial Summary

The aim of this study is to determine the effects of supplementation with n-3 fatty acid or placebo for 10 weeks on the expression of Sirt-1, AdipoR1 & AdipoR2 genes in the peripheral blood mononuclear cell (PBMC) and circulatory levels of Resistin, MCP-1 and Adiponectin of type2 diabetes patient

Clinical Trial Description

The aim of this study is to determine of the effects of supplementation with n-3 fatty acid or placebo for 10 weeks on the expression of Sirt-1, AdipoR1(adiponectin receptor 1) & AdipoR2 (adiponectin receptor 2) genes in the peripheral blood mononuclear cell (PBMC) and circulatory levels of Resistin, MCP-1 (Monocyte Chemoattractant Protein-1) and Adiponectin of type2 diabetes patient. In this randomized, double-blind clinical trial, placebo-controlled, 88 men and women with type 2 diabetes are enrolled in the study from the Iranian Diabetes Association. After signing informed consent all individuals complete a general information form , 24-hour food recall for 3 days and beck depression questionnaire will be taken from the participants at the beginning and the end of the study. Selected samples are randomly classified into 2 blocks of groups receiving supplement and placebo. The supplement group, will receive mg 1800mg EPA(Eicosapentaenoic acid ) & 900mg DHA( docosahexaenoic acid) (total=2700mg) for 10 weeks and the placebo group will also receive placebo (containing 2700 mg of edible paraffin) (similar in terms of color, shape and size). Patients are recommended to sustain their diets and medication dose (s) during the study and also advised to maintain a constant level of physical activity. Blood samples will be collected after 12 hours fasting and anthropometric variables, biochemical parameters, target gene expression and physical activity before and after the trial will be measured ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02261545
Study type	Interventional
Source	Tehran University of Medical Sciences
Contact
Status	Enrolling by invitation
Phase	Phase 4
Start date	September 2014
Completion date	February 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02028091` - Diabetes Mellitus - A Diagnosis Trial by Means of Non Invasive Measurements	N/A
Completed	`NCT01684813` - VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to Prasugrel	Phase 4
Completed	`NCT01252524` - Effect of Calcium Polycarbophil on Type II Diabetes Mellitus Control: a Randomized Double-blind Study	N/A
Recruiting	`NCT01311401` - Predictors of Future Type 2 Diabetes Mellitus in Circassians Minority in Israel	N/A
Completed	`NCT00563225` - 20 Week Bridging Study in Type II DM	Phase 3
Recruiting	`NCT01565096` - Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy	Phase 4
Completed	`NCT00151697` - LANN-study: Lantus, Amaryl, Novorapid, Novomix Study	Phase 3
Withdrawn	`NCT01453751` - Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered in Patients With Type II Diabetes	N/A
Not yet recruiting	`NCT01775059` - Collection of Performance Data From the Integrated Sensor and Infusion Set. TRIAL 4	N/A
Completed	`NCT01281098` - Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.	Phase 2
Completed	`NCT01669473` - A Primary Care, EHR- Based Strategy to Promote Safe and Appropriate Drug Use	N/A
Completed	`NCT02036372` - Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus	N/A
Completed	`NCT03258840` - EPA Supplementation on Vascular Inflammation, and Gene Expression of PON2 in Patients With Type II Diabetes Mellitus	N/A
Active, not recruiting	`NCT01386801` - Multicenter Research Study to Build a Repository to Study Chronic Diseases in Indiana	N/A
Completed	`NCT02144948` - Investigation of the Effect of E.-Coli-Nissle as Supporting Therapy to Standard Care of Diabetes Mellitus Type II	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

The Effect of n-3 Fatty Acid Supplementation on Serum Levels, and Gene Expression of type2 Diabetes Patient

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms